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Abstract
Introduction: Hip OF carries the highest morbidity and mortality. Previous studies revealed that individual genes/loci in the
Tumor Necrosis Factor (TNF) -Related Apoptosis-Inducing Ligand (TRAIL) pathway were associated with bone metabolism.
This study aims to verify the potential association between hip OF and TRAIL pathway.
Methods: Using genome-wide genotype data from Affymetrix 500 K SNP arrays, we performed novel pathway-based
association analyses for hip OF in 700 elderly Chinese Han subjects (350 with hip OF and 350 healthy matched controls).
Results: The TRAIL pathway achieved a significant p value (p=0.01) for association with hip OF. Among the 38 genes in the
TRAIL pathway, seven genes achieved nominally significant association with hip OF (p,0.05); the TNFSF10 (TRAIL) gene
obtained the most significant p value (p=1.70610
24). SNPs (rs719126, rs6533015, rs9594738, rs1805034, rs11160706) from
five genes (CFLAR, NFKB1, TNFSF11, TNFRSF11A, TRAF3) of the pathway had minor alleles that appear to be protective to hip
OF. SNPs (rs6445063 and rs4259415) from two genes (TNFSF10 and TNFRSF10B) of the pathway had minor alleles (A) that are
associated with an increased risk of hip OF, with the ORs (odds ratios) of 16.51 (95%CI:3.83–71.24) and 1.37 (95%CI:1.08–
1.74), respectively.
Conclusions: Our study supports the potential role of the TRAIL pathway in the pathogenesis of hip OF in Chinese Han
population. Further functional study of this pathway will be pursued to determine the mechanism by which it confers risk to
hip OF.
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Introduction
The prevalence of osteoporotic fractures (OF), especially hip
OF, has now become a significant public health burden due to the
associated high morbidity, mortality and tremendous health care
cost [1,2] The incidence of hip OF will reach 6.27 million
worldwide with a resultant cost of .$34 billion by the year 2050
[1]. The major demographic change of hip OF will occur in Asia.
In 1990, 26% of hip OF worldwide occurred in Asia, and this rate
could rise to 37% by the year 2025 and to 45% by the year 2050
[2]. Genetic factors play an important role in susceptibility to hip
OF [3,4]. However, to date, the genetic determination of hip OF is
still largely unknown.
A pathway-based association analysis approach is based on
gene set enrichment analysis. The method ranks genes/SNPs
genome-wide by the significance of association with a disease
phenotype to generate a gene list, then uses a statistic enrichment
score (ES) to examine whether a particular group of genes/SNPs
within a certain functional pathway is enriched at the top (or
bottom) of the list more than would be expected by chance [5].
This approach considers critical information about the interac-
tion of a set of functionally related genes and their joint effects,
and could potentially improve the power to detect genetic
variants working in functional pathways. The method may play a
major role in genetic analyses of complex diseases; for a pathway
that contributes to a disease’s risk, a single genetic variant within
that pathway may have only limited contribution to the risk that
might not be detectable (in regular genetic association analyses) if
not otherwise be detected at the whole pathway level. Recently,
through this new powerful approach, we have identified two
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[6,7].
Previous studies revealed importance in the pathogenesis of
bone metabolism for several individual genes/loci, or their
transcripts and proteins in Tumor Necrosis Factor (TNF)-Related
Apoptosis-Inducing Ligand (TRAIL) pathway, for example,
TRAIL, TRAILR1, TRAILR2, CFLAR, RANK, and OPG [8,9,10].
However, it is unknown if the TRAIL pathway may contribute to
osteoporotic fracture risk at the whole pathway level. We therefore
undertook a novel, pathway-based association study to assess
contribution of the pathway to hip OF risk.
Materials and Methods
Subjects
The study was approved by the institutional review board of
Xi’an Jiaotong University. After signing an informed consent
agreement, all subjects were assisted to complete a structured
questionnaire including anthropometric variables, lifestyles, and
medical history.
The sample consisted of 700 elderly Chinese Han subjects,
including 350 with osteoporotic (low trauma) hip fractures
(including 124 males and 226 females) and 350 controls (including
173 males and 177 females) (see Table 1 for the basic
characteristics of these subjects). All the subjects were unrelated
Chinese Han adults living in the city of Xi’an and its neighboring
areas. Inclusion criteria for cases were (i) onset age .55 years, all
female subjects were postmenopausal women; (ii) age ,80 years to
minimize the effect due to age, since previous studies showed that
approximately half of females aged 80 years or older have fractures
[11]; (iii) minimal or no trauma fractures, usually due to falls from
standing height or less; (iv) fracture site at femoral neck or inter-
trochanter regions; (v) hip fracture was identified/confirmed
through diagnosis of orthopedic surgeons/radiologists according
to radiological reports and X-rays. Patients with pathological
fractures and high-impact fractures (such as due to motor vehicle
accidents) were excluded.
Healthy control subjects were selected from our established
large database. They were geographically matched to the cases.
Inclusion criteria for controls were: (i) age at exam .55 years,
without any fracture histories (all female controls were postmen-
opausal); and (ii) not suffering from chronic diseases and conditions
that might potentially affect bone mass, structure, or metabolism.
The criteria may ensure that controls are less likely to suffer OF
during their remaining life span compared with the general
populations. The diseases/conditions mentioned above included
chronic disorders involving vital organs (heart, lung, liver, kidney,
brain), serious metabolic diseases (diabetes, hypo- and hyper-
parathyroidism, hyperthyroidism, etc.), other skeletal diseases
(Paget disease, osteogenesis imperfecta, rheumatoid arthritis,
etc.); chronic use of drugs affecting bone metabolism (e.g.,
hormone replacement therapy, corticosteroid therapy, anti-
convulsant drugs), and malnutrition conditions (such as chronic
diarrhea, chronic ulcerative colitis). In addition, subjects taking
anti-resorptive or bone anabolic agents/drugs, such as bisphos-
phonates were also excluded.
Genotyping and quality control
Genomic DNA was extracted from peripheral blood leukocytes
using a commercial isolation kit (Gentra systems, Minneapolis,
MN, USA) following the standard protocols. SNP genotyping was
performed using Affymetrix Human Mapping 500 K array set
(Affymetrix, Santa Clara, CA, USA). Genotyping calls were
determined from the fluorescent intensities using the dynamic
model (DM) algorithm [12] as well as the B-RLMM (Bayesian
Robust Linear Model with Mahalanobis Distance Classifier)
algorithm [13]. DM calls were used for quality control of the
genotyping experiment. BRLMM calls were used for the following
pathway-based analyses. SNPs with a sample call rate ,90%, with
allele frequencies extremely deviating from Hardy-Weinberg
equilibrium (p,10
27) and having a minor allele frequency
(MAF) ,0.01 in the total sample were discarded. The final SNP
number for the analyses is 371,258. This SNP set covers 14,642
genes and yielded an average marker spacing of ,7.9 kb
throughout the human genome. Among these SNPs, 350 belong
to the genes of the TRAIL pathway.
Statistical Analysis
Statistical analyses on individual SNPs were first conducted by
the Wald test implemented in Plink (version 1.03) [14] with age
and sex as covariates. The main procedures of pathway-based
analysis [15] are briefly summarized as follows:
(1) Generation of gene-phenotype association rank and calcula-
tion of ES: Among all the SNPs of a given gene Gi, the SNP
achieving the smallest p value in the single-marker association
tests was used to represent the magnitude of association
evidence of the gene. We ranked all genes by sorting their
statistic values from the largest to smallest, denoted as a vector
of the gene list L (r1,r2,…,rN). ‘‘N’’ equals to the total gene
number contained in the GeneChipH Human Mapping
500 K set arrays. ‘‘r’’ represents the gene-phenotype associ-
ation statistic value. Then, a weighted Kolmogorov-Smirnov–
like running-sum enrichment score (ESS) was calculated in
Equation 1. For the given pathway S composed of NS genes,
by walking down the gene list L, we increased the running-
sum statistic for the pathway when we encountered a gene in
























jri j and parameter p (designated as 1 here)
is designed to give higher weight to genes with extreme
statistic values. The magnitude of the increment depends on
the correlation of the gene with the phenotype. In short, ESS
is the maximum deviation from zero encountered in the
random walk. It will be high if the association signal is
enriched at the top of list L, reflected by the significance level
of observed ESS (i.e. nominal p value).
(2) Permutation and nominal significance assessment: The
phenotype data was shuffled and permutation (per) was done
Table 1. Characteristics of the study subjects.
Case (n=350) Control (n=350)
Age (years) 69.35 (7.41) 69.54 (6.09)
Weight (kg) 59.15 (12.05) 59.61 (10.84)
Height (cm) 162.84 (8.31) 159.41 (9.20)
Note: Data are shown as mean (standard deviation).
doi:10.1371/journal.pone.0021835.t001
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per through repeating steps (1),(2) to
estimate the nominal p value. A total of 1,000 permutations
were done to create a histogram of the corresponding
enrichment scores ESS
per,null for the given pathway/gene set
S. The nominal p value was estimated as the percentage of
permutations whose ESS
per were greater than the observed
ESS.
To detect possible population stratification that may lead to
spurious association results, we used Structure 2.2 software
(http://pritch.bsd.uchicago.edu/software.html) to investigate the
potential population substructure/stratification of the sample. The
program uses a Markov chain Monte Carlo (MCMC) algorithm to
cluster individuals into different cryptic sub-populations on the
basis of multi-locus genotype data [16]. We performed the analysis
assuming the number of population strata k=2 and using 1,000
un-linked SNPs randomly selected genome-wide. To confirm the
results achieved through Structure 2.2, we further tested
population stratification in our sample using EIGENSOFT 2.0
software that uses both principal component analysis and a
genomic control approach to correct possible statistical bias caused
by ancestral differences [17,18]. Reported p value was adjusted by
the l value estimated by genomic control method.
Results
Characteristics of study subjects
Basic characteristics of the 700 subjects are presented in Table 1.
The STRUCTURE program revealed that all subjects in this
Chinese sample were clustered together and could not be assigned
into any subgroups, indicating that there was no significant
population stratification within the sample. We also performed
analysis using EIGENSOFT [17] and confirmed the homogeneity
of the sample revealed by Structure; there is only one principal
component that is significant in the principal component analysis
(p,0.001), suggesting only one population ancestry existing for our
sample. Finally, we used the genomic control method [18] to
estimate the l value, which equals to 1.02, suggesting again there
is no population stratification in the sample.
Pathway-based association analysis
The TRAIL pathway, annotated by the Ambion GeneAssist
Pathway Atlas (Table 2), achieved a high NES of 1.76 with a p
value of 0.01. Among the 38 genes in the TRAIL pathway, the
gene with the most significant p value is TNFSF10 (TRAIL,
p=1.70610
24) (Table 3). Another six genes in the TRAIL
pathway, which also contribute positively to the ES (i.e., the genes
that ranked before or at the point of ES, also denoted as ‘‘leading
edge genes’’), are: CFLAR (c-FLIP, FLIP, p=3.17610
23),
TNFSF11 (RANKL, p=6.06610
23), TNFRSF11A (RANK, p=
7.63610
23), TNFRSF10B (TRAILR2, p=1.07610
22), TRAF3
(p=1.67610
22), and NFKB1 (NF-kB1, p=2.04610
22). Among
the 38 genes in the TRAIL pathway, 4 genes, NFKBIE, IKBKG,
RELB, DIABLO, were not covered by Affymetrix 500 k Array Set,
and the SNPs of the XIAP and APAF1 genes were discarded for
failure of passing the quality control criteria (Table 3).
For the top SNP of each gene, the effect size of the minor allele
is expressed by odds ratio (OR) derived from logistic regression
analyses. The OR value is interpreted in the standard manner. A
value of 1.0 indicates no effect. A value greater than 1.0 indicates
that the minor allele is associated with an increased hip OF risk,
and a value less than 1.0 implies that the minor allele is associated
with a decreased risk, hence may be protective. Among the 7 SNPs
representing the 7 leading edge genes, 5 SNPs had the protective
minor allele. They are: rs719126 of the CFLAR gene (minor allele
A, OR=0.05, 95%CI: 0.01–0.36), rs6533015 of the NFKB1 gene
(minor allele C,OR=0.76, 95%CI: 0.60–0.96), rs9594738 of the
TNFSF11 gene (minor allele C, OR=0.55, 95%CI: 0.36–0.84),
rs1805034 of the TNFRSF11A gene (minor allele C, OR=0.72,
95%CI: 0.57–0.92), and rs11160706 of the TRAF3 gene (minor
allele A, OR=0.75, 95%CI: 0.60–0.95). The other two SNPs,
rs6445063 in the TNFSF10 (TRAIL) gene and rs4259415 in the
TNFRSF10B (TRAILR2) gene, had a minor allele ‘‘A’’ with OR
values of 16.51 (95%CI: 3.83–71.24) and 1.37 (95%CI: 1.08–
1.74), respectively. The minor alleles of these two SNPs are
significantly associated with an increased risk of hip OF (P,0.05)
(Table 3).
Discussion
In this study, the TRAIL pathway was shown to be significantly
associated with hip OF (p=0.01) according to the pathway-based
association analysis. This is the first time that the TRAIL pathway
is implicated as an underlying factor for hip OF in Chinese. The
pathway may contribute to bone mass variation via regulating
osteoclast metabolism; previous findings have shown that the
TRAIL pathway play roles in modulating the differentiation,
function, survival and/or apoptosis of osteoclasts [19,20], which
may in turn accelerate bone resorption and consequently the
susceptibility to hip OF. The core process of TRAIL and the
functional interactions among the genes in the TRAIL pathway
are depicted in Figure 1.
TRAIL, also known as Apo2L, is a widely recognized member
of the tumor necrosis factor (TNF) ligand family [21,22]. TRAIL
is a typical type II membrane protein, binds to aggregates type I
transmembrane receptors with cytoplasmic death domains (DD),
which ultimately activate a protease cascade leading to apoptosis
[23]. Interacting with five different receptors of the TNF receptor
superfamily, TRAILR1, TRAILR2, TRAILR3, TRAILR4 and OPG,
the ligand is expressed constitutively in a wide range of tissues
[22,24,25], including bone-related cells, such as osteoclast or
osteoclast precursors. The binding of TRAIL to TRAILR2 (DR5),
which contains a conserved death domain (DD), may induce the
apoptosis of osteoclast [19]. This may play an important role in
the etiology of hip OF. TRAIL induces apoptosis in human
differentiated osteoclasts by means of TRAILR2, and activates an
intracellular pathway involving caspase-8 and Bid cleavage in the
active forms [19]. However, in this study, SNP rs6445063 from
TNFSF10 (TRAIL) gene and SNP rs4259415 from TNFRSF10B
(TRAILR2) gene of the pathway had minor alleles (A) that are
associated with an increased risk of hip OF, with the ORs (odds
ratios) of 16.51 (95%CI:3.83–71.24) and 1.37 (95%CI:1.08–
1.74), respectively. SNP rs6445063 is located on chromosome
3q26.31 and has never been studied previously. SNP rs4259415
is located on chromosome 8p21.3 and functions as intronic
enhancer. According to the FASTSNP program (http://fastsnp.
ibms.sinica.edu.tw), a change of ‘‘GRA’’ at rs4259415 may lead
to alter the binding sites for transcription factor from GATA-1 to
CdxA and TATA, which may change the function of apoptosis
related TRAILR2 gene and accordingly alter the apoptosis of
osteoclast. Furthermore, the apoptosis induced by death
receptors can be modulated at several levels. Intracellular anti-
apoptotic molecules can block the apoptotic signaling pathway.
Soluble receptors inhibit TRAIL-mediated apoptosis in part by
increasing baseline levels of CFLAR (c-FLIP), which competes
with caspase-8 for binding to FADD, and inhibits active caspases
[26]. Increased c-FLIP levels following exposure to soluble
factors may decrease the apoptosis of osteoclast. Intracellular
TRAIL Pathway on Hip Osteoporotic Fracture
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into alternative responses, i.e., the proliferation/survival of
osteoclast via activating NF-kB [20]. Although lack of bone
phenotype in mice with gene deletion of TRAIL was observed by
Sedger et al [27], Yen et al [28] showed that TRAIL can induce
osteoclast formation via direct engagement with the TRAIL death
receptor. Yen et al [28,29] suggested that TRAIL-induced
osteoclastogenesisis was dependent on activation of NF-kB,
ERK, and p38 MAP kinase and TRAF6 dependent. However
TRAF6 was not found to contribute positively to the ES as
TRAF3 in this study, suggests that there may be other factors that
also can function in this capacity.
Table 2. Component genes in the TRAIL pathway.
Gene Symbol Gene ID Genome Location Full name Protein Name
APAF1 317 12q23 apoptotic peptidase activating factor 1 APAF1
BID 637 22q11.1 BH3 interacting domain death agonist BID
CBL 867 11q23.3 Cas-Br-M (murine) ecotropic retroviral transforming sequence c-Cbl
REL 5966 2p13-p12 v-rel reticuloendotheliosis viral oncogene homolog (avian) c-Rel
CASP3 836 4q34 caspase 3, apoptosis-related cysteine peptidase Caspase3
CASP8 841 2q33-q34 caspase 8, apoptosis-related cysteine peptidase Caspase8
CASP9 842 1p36.21 caspase 9, apoptosis-related cysteine peptidase Caspase9
CYCS 54205 7p15.3 cytochrome c, somatic CytoC
DAP3 7818 1q22 death associated protein 3 DAP3
TNFRSF10C 8794 8p22-p21 tumor necrosis factor receptor superfamily, member 10c, decoy without an
intracellular domain
DCRI
TNFRSF10D 8793 8p21 tumor necrosis factor receptor superfamily, member 10d, decoy with truncated
death domain
DCR2
FADD 8772 11q13.3 Fas (TNFRSF6)-associated via death domain FADD
CFLAR 8837 2q33-q34 CASP8 and FADD-like apoptosis regulator c-FLIP, FLIP
NFKBIA 4792 14q13 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha I-KappaB-Alpha
NFKBIB 4793 19q13.1 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta I-KappaB-Beta
NFKBIE 4794 6p21.1 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon I-KappaB-Epsilon
CHUK 1147 10q24-q25 conserved helix-loop-helix ubiquitous kinase IKK-Alpha
IKBKB 3551 8p11.2 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta IKK-Beta
Gene Symbol Gene ID Genome Location Full name Protein Name
IKBKE 9641 1q32.1 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon I-KK-Epsilon
IKBKG 8517 Xq28 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma I-KK-Gamma
NFKB1 4790 4q24 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 NF-KappaB1
NFKB2 4791 10q24 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) NF-KappaB2
TNFRSF11B 4982 8q24 tumor necrosis factor receptor superfamily, member 11b OPG
TNFSF11 8600 13q14 tumor necrosis factor (ligand) superfamily, member 11 RANKL
PARP1 142 1q41-q42 poly (ADP-ribose) polymerase 1 PARP
TNFRSF11A 8792 18q22.1 tumor necrosis factor receptor superfamily, member 11a, NFKB activator RANK
RELA 5970 11q13 v-rel reticuloendotheliosis viral oncogene homolog A (avian) RelA
RELB 5971 19q13.32 v-rel reticuloendotheliosis viral oncogene homolog B RelB
DIABLO 56616 12q24.31 diablo homolog (Drosophila) SMAC
TRAF1 7185 9q33-q34 TNF receptor-associated factor 1 TRAF1
TRAF2 7186 9q34 TNF receptor-associated factor 2 TRAF2
TRAF3 7187 14q32.32 TNF receptor-associated factor 3 TRAF3
TRAF4 9618 17q11-q12 TNF receptor-associated factor 4 TRAF4
TRAF6 7189 11p12 TNF receptor-associated factor 6 TRAF6
TNFSF10 8743 3q26 tumor necrosis factor (ligand) superfamily, member 10 TRAIL
TNFRSF10A 8797 8p21 tumor necrosis factor receptor superfamily, member 10a TRAILR1
TNFRSF10B 8795 8p22-p21 tumor necrosis factor receptor superfamily, member 10b TRAILR2
XIAP 331 Xq25 X-linked inhibitor of apoptosis XIAP
Note: (1) TRAIL, TNF-Related Apoptosis-Inducing Ligand.
(2) The Gene ID was retrieved from NCBI GenBank (http://www.ncbi.nlm.nih.gov/Genbank/).
doi:10.1371/journal.pone.0021835.t002
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identified as a decoy receptor for RANKL [30] later found to be
able to bind TRAIL [31]. OPG acts as antagonist for osteoclast
apoptosis induced by TRAIL. But when OPG binds to the RANKL
on the surface of osteoblast/bone matrix, it prevents RANKL from
binding to its receptor, RANK, which inhibits the formation,
activation and survival of multinucleated osteoclasts. In this
process, the RANKL/OPG ratio is an important determinant of
bone mass and skeletal integrity [32]. Up-regulation of the RANKL
gene increases the RANKL/OPG ratio and enhances bone loss
Table 3. Association Results for the SNPs of Top Significance for Each Gene in the TRAIL Pathway.




APAF1 - 12 - - - - - -
BID rs424708 22 16588746 Downstream 0.07899 C 0.012 0.35 (0.11–1.13)
CBL rs4938638 11 118580639 Downstream 0.3039 C 0.127 0.84 (0.60–1.17)
REL rs842627 2 60994311 Downstream 0.08129 A 0.127 1.38 (0.96–1.99)
CASP3 rs4862379 4 185849707 Downstream 0.1001 C 0.081 1.40 (0.94–2.09)
CASP8 rs6723097 2 201954124 Intron 0.4147 C 0.468 0.91 (0.73–1.14)
CASP9 rs2042369 1 15715831 Intron 0.1818 A 0.039 0.66 (0.36–1.22)
CYCS rs10239907 7 24905619 Upstream 0.1457 C 0.290 1.20 (0.94–1.53)
DAP3 rs821551 1 152501653 Intron 0.3871 A 0.180 0.88 (0.67–1.17)
TNFRSF10C rs10111172 8 23025036 Intron 0.24 C 0.173 0.84 (0.64–1.12)
TNFRSF10D rs4278155 8 23052724 Intron 0.4 C 0.441 0.91 (0.73–1.13)
FADD rs11604809 11 69722984 Downstream 0.9726 C 0.466 1.00 (0.81–1.23)
CFLAR rs719126 2 201726075 Intron 0.00317 A 0.015 0.05 (0.01–0.36)
NFKBIA rs10132268 14 35017365 Upstream 0.1129 A 0.431 1.19 (0.96–1.46)
NFKBIB rs2241704 19 44088175 Intron 0.9237 A 0.120 0.98 (0.71–1.37)
NFKBIE - 6 - - - - -
CHUK rs7909855 10 101957202 Intron 0.2635 C 0.460 0.88 (0.70–1.10)
IKBKB rs10094577 8 42206733 Upstream 0.4423 C 0.013 0.68 (0.25–1.83)
IKBKE rs2871360 1 203065616 Downstream 0.2916 C 0.428 0.89 (0.71–1.11)
IKBKG - X - - - - -
NFKB1 rs6533015 4 103712711 Upstream 0.02041 C 0.336 0.76 (0.60–0.96)
NFKB2 rs11574851 10 104150949 Coding exon 0.4637 C 0.058 1.20 (0.74–1.96)
TNFRSF11B rs7816831 8 119792244 Upstream 0.07085 C 0.201 1.29 (0.98–1.69)
TNFSF11 rs9594738 13 41850145 Upstream 0.00606 C 0.080 0.55 (0.36–0.84)
PARP1 rs3219058 1 222879529 Intron 0.1564 C 0.318 0.85 (0.67–1.07)
TNFRSF11A rs1805034 18 58178221 Coding exon 0.00763 C 0.314 0.72 (0.57–0.92)
RELA rs1466462 11 65175940 Intron 0.7124 A 0.193 0.95 (0.72–1.25)
RELB - 19 - - - - -
DIABLO - 12 - - - - -
TRAF1 rs2416804 9 120755950 Intron 0.7757 C 0.472 1.03 (0.83–1.28)




TRAF2 rs2811757 9 137071341 Intron 0.4854 A 0.131 0.88 (0.61–1.26)
TRAF3 rs11160706 14 102431489 Intron 0.01667 A 0.341 0.75 (0.60–0.95)
TRAF4 rs4794836 17 24106837 Downstream 0.4349 A 0.253 1.10 (0.87–1.40)
TRAF6 rs2201845 11 36512834 Downstream 0.3038 C 0.040 0.74 (0.42–1.31)
TNFSF10 rs6445063 3 173676334 Downstream 0.00017 A 0.024 16.51 (3.83–71.24)
TNFRSF10A rs6557634 8 23116201 Intron 0.1974 C 0.022 1.65 (0.77–3.51)
TNFRSF10B rs4259415 8 22957513 Intron 0.0107 A 0.298 1.37 (1.08–1.74)
XIAP - X - - - - -
Note: (1) The SNPs significantly associated with hip OF are shown in bold.
(2)
aMinor allele of each SNP.
(3)
bMinor allele frequency calculated in our sample.
(4)
cPer-allele effect size of the minor allele is expressed by odds ratio (OR) and the 95% confidence interval of OR.
doi:10.1371/journal.pone.0021835.t003
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and rs1805034)o fRANKL and RANK with hip OF.
NF-kB1 (p50) is a subunit of NF-kB transcriptional factor
complex. The balance of survival (anti-apoptotic) and death
(apoptotic) signals through NF-kB activation cascades results in
normal bone homeostasis and healthy remodeling [33]. NF-kB
activation through RANK/RANKL signal pathway is closely
related with osteoporosis and the bone resorbing activity of
osteoclasts [34]. After RANKL binds to RANK, a key step in
downstream signaling is binding of TRAFs to specific sites of the
cytoplasmic domain of RANK [20,35,36]. Stimulation of RANK
results in strong NF-kB activation. NF-kB1(p50) is an important
signal for osteoclast development and osteoclast function. More-
over, NF-kB can be activated in many signal cascades related to
bone metabolism, e.g., NF-kB activation through the Fas/FasL
system leads to enhanced osteoclastogenesis and reduced apoptosis,
and it may also cause apoptotic cell death in osteoblasts [37].
Population stratification is an important source of spurious
association in genetic association studies [38,39]. However, these
factors are unlikely to exist in our sample to interfere with our
pathway-based association results. Our cohort came from an
apparently homogenous Chinese north-west Han ethnicity
population, living in Xi’an city and its neighboring areas. More
importantly, in the analyses using Structure 2.2 [40], all subjects
used in our study consistently clustered together as a single group,
suggesting no significant population substructure. In the analysis
using EIGENSTRAT [17], the measure for population stratifica-
tion, l, was very close to 1, which also suggests no stratification in
our cohort. For the above reasons, our association results are
unlikely to be plagued by spurious associations due to population
admixture/stratification.
In summary, we applied a pathway-based analysis method to
identify functional gene sets associated with hip OF. The
significant enrichment of the TRAIL pathway genes among the
top ranking genes associated with hip OF, together with the
pathway’s functional relevance to bone metabolism, strongly
supports the important role of TRAIL in human hip OF risk.
Further detailed and specific functional studies of the TRAIL
pathway will be pursued to provide new insights into the etiology
of hip OF.
Figure 1. TRAIL pathway and the gene-gene interaction. The binding of TRAIL to TRAILR2 may induce the apoptosis of osteoclast. Increased c-
FLIP levels may decrease the apoptosis of Osteoclast. The osteoclast apoptosis signal transduced by TRAIL/TRAILR2 was transformed to activate NF-
kB. A key step in downstream signaling of RANKL/RANK is binding of TRAFs to RANK. Stimulation of RANK also results in strong NF-kB activation. NF-
kB1(p50) is an important signal for osteoclast development and osteoclast function.
doi:10.1371/journal.pone.0021835.g001
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